



THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

WEST et al.

Serial No.: 10/551,202

Filed: April 14, 2004

Art Unit: (not yet assigned)

Examiner: (not yet assigned)

Atty. Docket No.: 05-221-US

**PHOSPHATES OF SECONDARY
ALCOHOLS**

Commissioner for Patents
MAIL STOP PETITION
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This Information Disclosure Statement is filed in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98. The items listed on the enclosed Form PTO-1449 may be deemed to be pertinent to the above-identified application and are made of record to assist the Patent and Trademark Office in its examination of this application. The Examiner is respectfully requested to fully consider the items and to independently ascertain their teaching.

1. ☒ Enclosed is PTO Form 1449 (and a duplicate thereof).
2. ☒ Items listed on the enclosed Form PTO-1449
☐ that are not in the English language:
 - ☐ For each of the following items, an English-language abstract is enclosed: .
 - ☐ For each of the following items, a concise explanation of that item is incorporated in the specification of the above-identified application:

☐ For each of the following items, a corresponding U.S. or other English-language patent is enclosed or has been previously cited. Please consider the U.S. or other English-language patents in accordance with the procedure set forth in MPEP § 609.

☒ that are U.S. patents or publications, no copies are being provided in accordance with the Official Gazette Notice of August 5, 2003.

3. ☐ **Submission in Accordance with 37 CFR § 1.98(d).**

Any copy of the items listed on the enclosed Form PTO-1449 that is not enclosed with this Information Disclosure Statement was previously cited by or submitted to the Patent and Trademark Office in Application Serial No. [Ser. No.], filed [Date], of which the present application relies upon for an earlier filing date under 35 U.S.C. 120.

4. ☒ **Submission in Accordance with 37 CFR § 1.97(b).**

This Information Disclosure Statement is being filed

- ☐ With the application;
- ☐ Within three months of the filing date of a national application;
- ☐ Within three months of the date of entry of the national stage in an international application; or
- ☒ Before the mailing date of a first Office Action on the merits,

and NO FEE is due for consideration of this Information Disclosure Statement.

5. ☐ **Submission in Accordance with 37 CFR 1.97(c).**

This Information Disclosure Statement is being filed before the first mailing date of either

- ☐ A final action under § 1.113; or
- ☐ A notice of allowance under § 1.311.
- ☐ A fee is due for consideration of this Information Disclosure Statement and the fee is paid below; or
- ☐ This Information Disclosure Statement is accompanied by one of the certifications pursuant to 37 CFR § 1.97(e), and NO FEE is due for consideration of this Information Disclosure Statement.

6. ☐ **Submission in Accordance with 37 CFR 1.97(d).**

This Information Disclosure Statement is being filed after the mailing date of either

- ☐ A final action under § 1.113; or
- ☐ A notice of allowance under § 1.311,

whichever comes first, but before payment of the issue fee, and is accompanied by

- a. One of the certifications pursuant to 37 CFR § 1.97(e), which is set forth below;
- b. The attached petition requesting consideration of this Information Disclosure Statement; and
- c. The petition fee under 37 CFR § 1.17(i)(1), which is paid below.

7. **Certification Pursuant to 37 CFR 1.97(e).**

- ☐ The undersigned certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ The undersigned certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, or to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

8. **Fee Payment Being Made.**

- ☐ Enclosed
 - ☐ \$180.00 fee for submission under 37 CFR § 1.97(c).
 - ☐ \$180.00 fee for submission under 37 CFR § 1.97(d).
- ☐ A check in the amount of \$[Amount] to cover the fee payment is enclosed.
- ☐ Charge the fee to Deposit Account No. 18-0582. A duplicate copy of this communication is attached.

☒ The Director is hereby authorized to charge payment of any additional fees associated with this Information Disclosure Statement or credit any overpayment to Deposit Account No. 18-0582. A duplicate copy of this communication is enclosed.

Respectfully submitted,




James G. Dilmore, Patent Agent
Reg. No. 51,618

Dated: June 29, 2006

REED SMITH LLP
P.O. Box 488
Pittsburgh, PA 15230-0488
(412) 288-3813

Agent for Applicants

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) U.S. PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (37 CFR 1.98(b))	ATTY. DOCKET NO. 05-221-US	SER. NO. (Not yet assigned)
	APPLICANT WEST et al.	
	FILING DATE September 27, 2005	GROUP (Not yet assigned)



U.S. PATENT DOCUMENTS

Examiner Initial	Cite No. ¹	Patent Number	Issue Date	Patentee	Class/ Subclass	Filing Date
		4299906	11/1981			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner Initial	Document Number	Publication Date	Country or Patent Office	Class/ Subclass	Translation Yes/No
	43870/00	12/2000	AU		
	925961	5/1982	SU		
	1121683	7/1968	GB		
	2227662	8/1990	GB		
	2001/046204	6/2001	WO		

OTHER DOCUMENTS

(Including Author, Title, Date, Relevant Pages, Place of Publication)

Examiner Initial	Cite No. ¹	
		Derwent Abstract Accession No. 26921 K/11, SU 925961, 5/1982
		Derwent Abstract Accession No. 1981-89192D/48, US 4299906, 11/1981
		STN File CA, Abstract 139:399976, Puratchikody, A., et al, "Reverse Phase-High Performance Liquid Chromatographic Determination of Atorvastatin Calcium in Solid Dosage Forms", Pharma Review (2003), 1(2), 79-80, 83

EXAMINER	DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.